• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

First-line use of contact aspiration not superior to stent retriever for acute ischemic stroke

byAdarsh ManjunathandMichael Milligan
August 4, 2017
in Chronic Disease
Reading Time: 2 mins read
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Share on FacebookShare on Twitter

1. In patients presenting with acute ischemic stroke, first-line use of contact aspiration was not found to result in an increased successful revascularization rate compared to first line use of a stent retriever.

2. The degree of disability post-procedure and the procedure-related serious adverse events did not differ significantly.

Evidence Rating Level: 1 (Excellent)

Study Rundown: For patients with acute ischemic stroke, recent studies demonstrated the superiority of mechanical thrombectomy over standard medical management alone. Thus, increasing studies have looked at different methods of thrombectomy. Contact aspiration has gained popularity because it is thought to result in quicker revascularization at a lower cost, but others argue it may delay revascularization if the more thorough stent retriever technique is ultimately necessary. The purpose of this study was to evaluate whether first-line contact aspiration resulted in an increased successful revascularization rate compared to first line use of a stent retriever. In 381 patients with acute ischemic stroke who were randomized to first line contact aspiration or first line stent retriever in 8 stroke centers in France from 2015-2016, 85.4% in the contact aspiration group were successfully revascularized vs. 83.1% in the stent retriever group. This was not statistically significant. There were also no significant differences in adverse events.

Overall, this study suggests that first line contact aspiration did not result in an increased successful revascularization rate compared with first line stent retriever use. However, this study had a superiority design in order to detect a 15% difference, and so was not powered to detect a smaller but possibly important difference between groups. Finally, the centers where these procedures took place were all highly experienced and so the results may not be generalizable to all centers.

Click to read the study, published in JAMA

RELATED REPORTS

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

Thrombectomy may improve functional independence in acute ischemic stroke with medium vessel occlusion

2 Minute Medicine Rewind April 20, 2026

Relevant Reading: Endovascular thrombectomy after large-vessel ischemic stroke: a meta-analysis of individual patient data from five randomized trials

In-Depth [randomized controlled trial]: This study included 381 patients who presented with acute ischemic stroke and large vessel occlusion in the anterior circulation within 6 hours of symptom onset. Patients were randomized to first line contact aspiration or first line stent retriever immediately prior to mechanical thrombectomy at 8 comprehensive stroke centers in France from 2015-2016. Mean time from symptom onset to arterial puncture was 227 minutes (interquartile range 180-280 minutes). The primary outcome was the proportion of patients with successful revascularization defined as a modified Thrombolysis in Cerebral Infraction score of 2b or 3. A total of 85.4% in the contact aspiration group were successfully revascularized vs. 83.1% in the stent retriever group (OR 1.2 [CI95% 0.68-2.1], p = 0.53; difference 2.4% [CI95% -5.4% to 9.7%]). Secondary outcomes were degree of disability as assessed by the modified Rankin scale score at 90 days, change in National Institutes of Health Stroke Scale score at 24 hours, all-cause mortality at 90-days, and procedure-related serious adverse events. No secondary outcomes were statistically significant between groups.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: endovascular thrombectomyischemic stroke
Previous Post

Despite adverse events, corticosteroids may benefit patients with IgA nephropathy

Next Post

Features predicting treatment failure in acute otitis media

RelatedReports

Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
No obesity paradox found between BMI, stroke, and death
Neurology

Thrombectomy may improve functional independence in acute ischemic stroke with medium vessel occlusion

May 26, 2026
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Weekly Rewinds

2 Minute Medicine Rewind April 20, 2026

April 20, 2026
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Chronic Disease

Virtual reality rehabilitation is safe and feasible for upper extremity recovery after subacute ischemic stroke

February 25, 2026
Next Post
Features predicting treatment failure in acute otitis media

Features predicting treatment failure in acute otitis media

Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

2 Minute Medicine Rewind August 7, 2017

American Academy of Pediatrics recommends standards for adverse event disclosures

Expansion of medical home program to Medicare patients not linked with improved quality or cost-reduction

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The rate of urethrocutaneous fistula following caudal and penile blocks for hypospadias repair may be similar
  • Adjuvant chemotherapy not linked to improved outcomes in localized appendiceal adenocarcinoma
  • Deep learning model improved cancer recurrence prediction for pediatric glioma using serial imaging
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.